Abstract:The causal genes for a large proportion of hereditary colorectal adenomas and early-onset colorectal cancer (CRC) remain to be identified. Here, we identified a germline heterozygous stop-gain mutation p.Arg1953X (rs150312701) of the POLQ (DNA Polymerase Theta) gene, which is co-segregated with disease status, by whole-exome sequencing of twelve hereditary CRC pedigrees. The mutation was validated in an independent pedigree, resulting in ten p.Arg1953X carriers from two CRC families. Mechanically, the heterozygous nonsense mutation led to compensated overexpression of the mRNA with wild-type POLQ allele under DNA damage stress, resulting in hyperactivation of the error-prone theta mediated end-joining (TMEJ) DNA repair pathway, which enables the survival of mutation-enriched cells. Concordantly, tumor tissues from p.Arg1953X mutation carriers showed microsatellite instability and hypermutation, and were resistant to radiotherapy. We found that an FDA-approved antibiotic Novobiocin inhibits the POLQ -mediated TMEJ pathway, eliminates the p.Arg1953X mutation-related resistance to DNA damage, finally benefits tumor radiotherapy. Collectively, we defined a POLQ-mutated CRC type and suggested for a mutation-based potential target therapeutic strategy. ### Competing Interest Statement The authors have declared no competing interest. ### Funding Statement The study was supported by the National Natural Science Foundation of China and the Applied Basic Research Foundation of Yunnan Province. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: All studies were conducted with the approval of the ethics committee of Kunming Medical University (2017-3), and all participants provided written informed consent. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes

A germline heterozygous nonsense mutation causes hereditary colorectal cancer

A Germline Heterozygous POLQ Nonsense Mutation Causes Hereditary Colorectal Cancer

Nonsense suppression induces read‐through of a novel BMPR1A variant in a Chinese family with hereditary colorectal cancer

Germline Mutation of RPS20, Encoding a Ribosomal Protein, Causes Predisposition to Hereditary Nonpolyposis Colorectal Carcinoma Without DNA Mismatch Repair Deficiency

Germline Variants of CYBA and TRPM4 Predispose to Familial Colorectal Cancer

Modeling the Etiology of p53-mutated Cancer Cells

Germline Mutations in a DNA Repair Pathway Are Associated with Familial Colorectal Cancer.

Whole Exome Sequencing Of Ulcerative Colitis-Associated Colorectal Cancer Based On Novel Somatic Mutations Identified In Chinese Patients

A Functional Variant of IC 53 Correlates with the Late Onset of Colorectal Cancer

A de novo germline mutation of APC for inheritable colon cancer in a Chinese family using multigene next generation sequencing.

The orphan nuclear receptor NR0B2 could be a novel susceptibility locus associated with microsatellite‐stable, APC mutation‐negative early‐onset colorectal carcinomas with metabolic manifestation

Inherited BRCA1 and RNF43 pathogenic variants in a familial colorectal cancer type X family

RNF43 Pathogenic Germline Variant in a Family with Colorectal Cancer.

Germline Gain‐Of‐Function Mmp11 Variant Results In An Aggressive Form Of Colorectal Cancer

Concurrent Genetic Alterations in DNA Polymerase Proofreading and Mismatch Repair in Human Colorectal Cancer

Germline NPAT inactivating variants as cause of hereditary colorectal cancer

Whole-exome sequencing identifies rare pathogenic variants in new predisposition genes for familial colorectal cancer

Pathogenic Germline Mutations of DNA Repair Pathway Components in Early-Onset Sporadic Colorectal Polyp and Cancer Patients

Tu2063 Germline Mutations in Two Hereditary Early On-Set Gastric Cancer Families

A nonsense mutation in the Xeroderma pigmentosum complementation group F (XPF) gene is associated with gastric carcinogenesis

A novel RBBP8(p.E281*) germline mutation is a predisposing mutation in familial hereditary cancer syndrome